176 related articles for article (PubMed ID: 33622766)
21. Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial.
de la Torre R; de Sola S; Hernandez G; Farré M; Pujol J; Rodriguez J; Espadaler JM; Langohr K; Cuenca-Royo A; Principe A; Xicota L; Janel N; Catuara-Solarz S; Sanchez-Benavides G; Bléhaut H; Dueñas-Espín I; Del Hoyo L; Benejam B; Blanco-Hinojo L; Videla S; Fitó M; Delabar JM; Dierssen M;
Lancet Neurol; 2016 Jul; 15(8):801-810. PubMed ID: 27302362
[TBL] [Abstract][Full Text] [Related]
22. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.
Tourbah A; Lebrun-Frenay C; Edan G; Clanet M; Papeix C; Vukusic S; De Sèze J; Debouverie M; Gout O; Clavelou P; Defer G; Laplaud DA; Moreau T; Labauge P; Brochet B; Sedel F; Pelletier J;
Mult Scler; 2016 Nov; 22(13):1719-1731. PubMed ID: 27589059
[TBL] [Abstract][Full Text] [Related]
23. N-Acetyl Cysteine as a Neuroprotective Agent in Progressive Multiple Sclerosis (NACPMS) trial: Study protocol for a randomized, double-blind, placebo-controlled add-on phase 2 trial.
Schoeps VA; Graves JS; Stern WA; Zhang L; Nourbakhsh B; Mowry EM; Henry RG; Waubant E
Contemp Clin Trials; 2022 Nov; 122():106941. PubMed ID: 36182028
[TBL] [Abstract][Full Text] [Related]
24. A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis.
Walker JE; Giri SN; Margolin SB
Mult Scler; 2005 Apr; 11(2):149-58. PubMed ID: 15794387
[TBL] [Abstract][Full Text] [Related]
25. Safety and preliminary efficacy on cognitive performance and adaptive functionality of epigallocatechin gallate (EGCG) in children with Down syndrome. A randomized phase Ib clinical trial (PERSEUS study).
Cieuta-Walti C; Cuenca-Royo A; Langohr K; Rakic C; López-Vílchez MÁ; Lirio J; González-Lamuño Leguina D; González TB; García JG; Roure MR; Aldea-Perona A; Forcano L; Gomis-Gonzalez M; Cés SV; Lacaille F; Ravel A; Mircher C; Walti H; Janel N; Dairou J; Lévy M; Durand S; Dierssen M; Sacco S; Fornell RT;
Genet Med; 2022 Oct; 24(10):2004-2013. PubMed ID: 35951014
[TBL] [Abstract][Full Text] [Related]
26. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
27. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
28. Phase I/II clinical trial of efficacy and safety of EGCG oxygen nebulization inhalation in the treatment of COVID-19 pneumonia patients with cancer.
Yin X; Zhu W; Tang X; Yang G; Zhao X; Zhao K; Jiang L; Li X; Zhao H; Wang X; Yan Y; Xing L; Yu J; Meng X; Zhao H
BMC Cancer; 2024 Apr; 24(1):486. PubMed ID: 38632501
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study.
Klopstock T; Tricta F; Neumayr L; Karin I; Zorzi G; Fradette C; Kmieć T; Büchner B; Steele HE; Horvath R; Chinnery PF; Basu A; Küpper C; Neuhofer C; Kálmán B; Dušek P; Yapici Z; Wilson I; Zhao F; Zibordi F; Nardocci N; Aguilar C; Hayflick SJ; Spino M; Blamire AM; Hogarth P; Vichinsky E
Lancet Neurol; 2019 Jul; 18(7):631-642. PubMed ID: 31202468
[TBL] [Abstract][Full Text] [Related]
30. Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: a randomized clinical trial.
Mähler A; Steiniger J; Bock M; Klug L; Parreidt N; Lorenz M; Zimmermann BF; Krannich A; Paul F; Boschmann M
Am J Clin Nutr; 2015 Mar; 101(3):487-95. PubMed ID: 25733633
[TBL] [Abstract][Full Text] [Related]
31. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
Zajicek J; Ball S; Wright D; Vickery J; Nunn A; Miller D; Cano MG; McManus D; Mallik S; Hobart J;
Lancet Neurol; 2013 Sep; 12(9):857-865. PubMed ID: 23856559
[TBL] [Abstract][Full Text] [Related]
32. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA
Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548
[TBL] [Abstract][Full Text] [Related]
33. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study.
Filippi M; Wolinsky JS; Comi G;
Lancet Neurol; 2006 Mar; 5(3):213-20. PubMed ID: 16488376
[TBL] [Abstract][Full Text] [Related]
34. Acute EGCG supplementation reverses endothelial dysfunction in patients with coronary artery disease.
Widlansky ME; Hamburg NM; Anter E; Holbrook M; Kahn DF; Elliott JG; Keaney JF; Vita JA
J Am Coll Nutr; 2007 Apr; 26(2):95-102. PubMed ID: 17536120
[TBL] [Abstract][Full Text] [Related]
35. Combined epigallocatechin-3-gallate and resveratrol supplementation for 12 wk increases mitochondrial capacity and fat oxidation, but not insulin sensitivity, in obese humans: a randomized controlled trial.
Most J; Timmers S; Warnke I; Jocken JW; van Boekschoten M; de Groot P; Bendik I; Schrauwen P; Goossens GH; Blaak EE
Am J Clin Nutr; 2016 Jul; 104(1):215-27. PubMed ID: 27194304
[TBL] [Abstract][Full Text] [Related]
36. Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial.
Cambron M; Mostert J; Haentjens P; D'Hooghe M; Nagels G; Willekens B; Heersema D; Debruyne J; Van Hecke W; Algoed L; De Klippel N; Fosselle E; Laureys G; Merckx H; Van Wijmeersch B; Vanopdenbosch L; Verhagen W; Hupperts R; Hengstman G; Michiels V; Van Merhaegen-Wieleman A; De Keyser J
Trials; 2014 Jan; 15():37. PubMed ID: 24460863
[TBL] [Abstract][Full Text] [Related]
37. Effect of epigallocatechin-gallate on inner retinal function in ocular hypertension and glaucoma: a short-term study by pattern electroretinogram.
Falsini B; Marangoni D; Salgarello T; Stifano G; Montrone L; Di Landro S; Guccione L; Balestrazzi E; Colotto A
Graefes Arch Clin Exp Ophthalmol; 2009 Sep; 247(9):1223-33. PubMed ID: 19290537
[TBL] [Abstract][Full Text] [Related]
38. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.
Molyneux PD; Kappos L; Polman C; Pozzilli C; Barkhof F; Filippi M; Yousry T; Hahn D; Wagner K; Ghazi M; Beckmann K; Dahlke F; Losseff N; Barker GJ; Thompson AJ; Miller DH
Brain; 2000 Nov; 123 ( Pt 11)():2256-63. PubMed ID: 11050025
[TBL] [Abstract][Full Text] [Related]
39. Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.
Connick P; De Angelis F; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S; Chataway J;
BMJ Open; 2018 Aug; 8(8):e021944. PubMed ID: 30166303
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
